
CDC investigating hospitalizations of five people who recently received chikungunya vaccine
The US Centers for Disease Control and Prevention is currently investigating five hospitalizations that occurred in people who had recently received a vaccine that prevents disease caused by the chikungunya virus.
In a notice posted Tuesday on a vaccine information page for health-care providers, the CDC said that the people, all 65 and older, were hospitalized for cardiac or neurologic events following vaccination with IXCHIQ, the only chikungunya vaccine currently licensed in the United States.
CNN has reached out to the CDC for comment.
Chikungunya virus is typically spread to people through the bite of an infected mosquito. Most adults don't receive the vaccine; it is sometimes recommended for certain travelers at an increased risk of being exposed to the mosquito-borne disease.
'This topic will be discussed at an upcoming meeting of the Advisory Committee on Immunization Practices (ACIP). Healthcare providers should discuss the benefits and risks of vaccination with individual travelers based on their age, destination, trip duration, and planned activities,' the CDC's online notice said in part.
The chikungunya vaccine and surveillance for adverse events originally were scheduled to be discussed in an ACIP meeting Wednesday, according to a draft meeting agenda, but that meeting has been postponed.
Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center and ACIP liaison, said the CDC investigation is an example of the agency's vaccine surveillance system 'working excellently and sending out a signal' in detecting rare events that might deserve further investigation.
'And of course, the CDC and the local people who are taking care of these patients are working on that now, which is entirely appropriate. That's the way the system is supposed to work,' Schaffner said.
'Remember, we're still trying to work out whether this is a causal relationship or a coincidental one,' he said about the investigation, in which he is not directly involved. 'Let's not draw any conclusions yet. That's why they're doing the investigation.'
The IXCHIQ vaccine, administered as a single-dose shot into the muscle, contains a live, weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva, was the first vaccine approved by the US Food and Drug Administration to prevent disease caused by chikungunya virus. The approval, in November 2023, was for people 18 and older who are at increased risk of exposure to chikungunya virus.
'It's recommended in a very restricted way to travelers who are going to countries where there is a current outbreak of chikungunya virus infection, and also to travelers who are going to countries who had experienced an outbreak within the past five years,' Schaffner said. 'And also to laboratorians who work with the chikungunya virus in the laboratory.'
CNN has reached out to Valneva for comment. Prescribing information for the vaccine states, 'Vaccination with IXCHIQ may cause severe or prolonged chikungunya-like adverse reactions.'
Chikungunya virus circulates in tropical and subtropical regions. In the United States, locally acquired infections have not been reported since 2019, according to the CDC. But cases and outbreaks had been identified in more than 100 countries in the Americas, Africa, Asia, Europe, and the Indian and Pacific Oceans.
Symptoms of chikungunya infections include fever, joint pain, headache, muscle pain, joint swelling or rash, according to the CDC, and the best way to prevent chikungunya is to avoid mosquito bites. There are currently no medications to treat chikungunya, but infected people may feel better with rest, fluids and over-the-counter medications for pain and fever.
In Tuesday's notice, the CDC said that common adverse reactions following vaccination that occurred in more than 10% of vaccinated people in clinical trials included tenderness, headache, fatigue, muscle pain, joint pain, fever and nausea. In some people, 'severe or prolonged chikungunya-like adverse reactions' occurred.
Chikungunya-like reactions included 'fever, joint pain, headache, rash, and can also include cardiac and neurologic conditions which were serious in two cases,' Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who was not involved in the clinical studies, said in an email Wednesday.
The CDC's notice encouraged health-care providers 'to report all adverse events that might be caused by vaccination to the CDC/FDA Vaccine Adverse Events Reporting System (VAERS),' by submitting a report online or using a PDF form.
'The robust vaccine safety surveillance system often identifies extremely rare adverse effects of vaccines after approval,' said Barouch, an infectious disease expert not involved in the CDC investigation.
When the vaccine was approved in 2023, the FDA noted that its safety was evaluated in two clinical studies conducted in North America in which about 3,500 adults received a dose of the vaccine, with one study including about 1,000 participants who received a placebo. Severe chikungunya-like adverse reactions occurred in 1.6% of IXCHIQ recipients and none of the placebo recipients, according to the FDA.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Former White House COVID-19 response coordinator Ashish Jha, who served under former President Biden, criticized the decision by Health and Human Services Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal on Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look, what he said in his op-ed was a series of nonsense about a group of individuals, experts …who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern regarding Kennedy's raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused members of the Advisory Committee on Immunization Practices of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Forbes
6 hours ago
- Forbes
Firing Of Vaccine And Cancer Advice Panels Raises Question, What Next?
WASHINGTON, DC: Secretary of Health and Human Services Robert F. Kennedy Jr. testifies before the ... More Senate Committee on Health, Education, Labor, and Pensions on Capitol Hill on May 20, 2025. Kennedy testified Department of HHS's proposed 2026 fiscal year budget.(Photo by) Earlier this year, the National Institutes of Health dismantled the National Cancer Institute's Board of Scientific Advisors, which had 28 members. And now Health and Human Services Secretary Robert F. Kennedy Jr fired the entire 17-member Advisory Committee on Immunization Practices that provides recommendations on vaccines to the Centers for Disease Control and Prevention. This raises the question, who's going to do the advising? With no replacement forthcoming, at NCI it would appear that the National Cancer Advisory Board will have to go it alone. At ACIP, it's likely Kennedy will appoint people to the advisory committee without a vaccine industry pedigree, including like-minded vaccine skeptics. The importance of having independent expert panels in the oncology and vaccine spaces is hard to overstate. Cancer is America's second-leading cause of death. NCI is the nation's premier funder of cancer research. And regarding vaccines, from smallpox inoculations—which began in the late 18th century and ended when the disease was eradicated in the 1970s—to mumps, rubella, tetanus, diphtheria, polio, measles, hepatitis B, human papilloma virus, respiratory syncytial virus, pneumococcal and COVID-19 immunizations, vaccinations have saved millions of lives and prevented life-threatening illnesses from occurring. What happens next in terms of decisions by Kennedy and the various HHS agencies will matter considerably to public health. Kennedy seeks to radically reshape the vaccine policy landscape as he ousts CDC's ACIP, which advises the CDC director on which vaccines approved by the Food and Drug Administration should be used; for example, recommending which groups of people ought to be vaccinated, at what doses and when. For decades, ACIP's guidance has been based on an independent, non-politicized review of the peer-reviewed scientific research as well as debate among the committee experts. ACIP's guidance is not binding, though CDC almost always follows it and provides recommendations to the public on what is to be included in the United States adult and childhood immunization schedules. In a press release issued by the Department of HHS on June 9th, Kennedy says he's doing this in order to restore the public's trust in vaccine science in America. It's unknown who Kennedy will hire to replace committee members, but it's possible that at least some of the people he appoints will share his skeptical views of vaccines. The Department of HHS said ACIP will still meet June 25-27, but with new membership. This means that between now and then, presumably we'll know the list of new members. In determining who's to be on the ACIP committee, Kennedy says he wants to eliminate conflicts of interest that panel members may have with the industry. But Science describes an already existing process in place for vetting candidates and probing for potential conflicts of interest. Indeed, looking at the current ACIP members, conflicts of interest aren't readily apparent among the large number of academics, a chief medical officer of a community health center, a state public health official and the owner of a family medicine practice. But Kennedy seems to view them differently. Given that several members have prior to their ACIP membership pursued research funded in part by grants to universities from the pharmaceutical industry, while others have advocated for certain childhood vaccinations, in Kennedy's eyes they're probably seen as part of the vaccine establishment. The NIH dismissed all 28 members of the Board of Scientific Advisors to the National Cancer Institute in late April. This board had been reviewing NCI-funded extramural research and education projects for nearly three decades, often doing its work in conjunction with the National Cancer Advisory Board. In making the termination decision, the NIH director Jay Bhattacharya cited a presidential executive order calling for the culling of 'unnecessary' federal committees. This order also included an edict that the HHS Secretary end the Advisory Committee on Long COVID and that the Administrator of the Centers for Medicare and Medicaid Services discontinue the Health Equity Advisory Committee The NCI's Board of Scientific Advisors was made up of leading cancer scientists, mostly from academia, across a wide range of disease specialties. Board members did their work as a panel voluntarily, offering a deep level of expertise to the NCI, specifically around setting research priorities and giving the broader scientific community input into the NCI's extramural programs. Whether the still-existing National Cancer Advisory Board can pick up the slack and be as independent are unclear. The NIH didn't just get rid of the NCI's Board of Advisors. The NCI has also begun to face large numbers of staff terminations and closures of programs. As STAT News reported, NIH fired virtually the entire NCI communications team and a substantial number of employees in the Office of Advocacy Relations. The NCI Outstanding Investigator award program was also canceled. More cuts are expected, as the NCI has been ordered to 'significantly' reduce its contracts budget. This budget can cover, among other things, support for clinical trials, certain lab scientists, a cancer registry to collect, store and manage data on persons with cancer, scientific databases and a repair service for critical lab equipment. On top of this, the New York Times is tallying the full extent of the cuts in research grant funding across all parts of the NIH, including the NCI. Currently, at least 2,500 grants have been canceled or delayed, impacting many therapeutic areas such as cancer, but also vaccine development and research on how to improve vaccination outreach.


The Hill
6 hours ago
- The Hill
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Former White House COVID-19 response coordinator Ashish Jha, who served under President Biden, criticized the decision by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look what he said in his op-ed was a series of nonsense about a group of individuals, experts…who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern about Kennedy raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused ACIP members of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.'